3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Lymphoma, Non-Hodgkin
4
Lymphoma
4
Leukemia
4
Vomiting
3
Neoplasms
3
Neoplasm Metastasis
3
Multiple Myeloma
3
Lymphoma, B-Cell
3
Hodgkin Disease
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Nausea
2
Myelodysplastic Syndromes
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Leukemia, Hairy Cell
2
Kidney Neoplasms
2
Hematologic Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma in Situ
2
Vulvar Neoplasms
1
Vulvar Diseases
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Alveolar Soft Part
1
Rectal Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Interventions
Cisplatin
76
Cetuximab
60
pembrolizumab
56
Radiotherapy, Intensity-Modulated
37
Radiotherapy
33
Carboplatin
31
Docetaxel
30
Fluorouracil
27
Nivolumab
26
Paclitaxel
20
Platinum
10
Albumin-Bound Paclitaxel
9
Surgical Procedures, Operative
8
Radiosurgery
8
Radiation
8
Erlotinib Hydrochloride
8
durvalumab
7
Bevacizumab
7
1,2-diaminocyclohexaneplatinum II citrate
7
epacadostat
6
Biopsy
6
Radiotherapy, Conformal
5
Ipilimumab
5
Immunoglobulin G
5
Gemcitabine
5
Capecitabine
5
130-nm albumin-bound paclitaxel
5
utomilumab
4
tremelimumab
4
palbociclib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Squamous Cell Carcinoma of Head and Neck
×
Diphenhydramine
×
Clear all
NCT03107182
2025-05-06
OPTIMA-II
University of Chicago
Phase 2
Completed
72 enrolled
14 charts